RDR Alert®

The common, concerning adverse effect requires a careful eye from clinicians and new therapy options.

MET inhibitor capmatinib may hold promise for a small subtype of patients with a non-small cell lung cancer, according to new ASCO 2019 findings.

Patients with the rare cancer condition requires both a collaborative physician network and proven therapies.

New phase 3 trial results show the monoclonal antibody plus pomalidomide and dexamethasone improves progression free survival and overall response rate among patients with RRMM.

Hu5F9-G4, aided by azacytidine, showed the potential to remove signals on cancer cells that would normally prevent a patient’s body from eliminating said cells.

Phase 3 results show the therapy plus recombinant human hyaluronidase is comparably safe and effective for patients with relapsed-refractory multiple myeloma.

A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.

New analysis shows patients from either of these populations often take longer to be diagnosed with leukemia or lymphoma than their male or median-income counterparts.

A new study shows a profound lack of genetic markers, allowing doctors to standardize treatment.

A new study shows that adding this pair of drugs reduces costs and side effects while increasing efficacy.

Investigators from St. Jude's Children Research Hospital presented the results of the phase 1 trial at ASCO 2019 in Chicago.

Investigators conducted an open-label, randomized, multi-center phase 2 study of VIT and vincristine with irinotecan without temozolomide that included 120 patients from 37 European centers.

FDA approved addition of OS to labeling based on results of the ADMIRAL trial.

BioMarin announced the investigative gene therapy reached pre-specified criteria for Factor VIII levels in adult patients with severe hemophilia A.

The first-in-class JAK1/JAK2 inhibitor from Incyte has become the first therapy to receive indication for these patients, which make up about half of the acute GVHD population.

Teduglutide (Gattex) has been approved as an injection for pediatric patients 1 year of age and older with Short Bowel Syndrome.

With approval Ruzurgi becomes first treatment for LEMS approved for children.

Tafamidis and tafamidis meglumine reported a greater survival rate in treated patients than those administered placebo, and reported a reduced rate of hospitalizations from cardiovascular problems.

Riluzole oral film (Exservan) was developed as an option for patients with ALS who have difficulty swallowing medication.

A new gene expression-tracking study, conducted under a novel computation, could provide investigators material to make diagnosis and therapeutic breakthroughs.

Randomized, placebo-controlled trial found a 50% reduction in absolute eosinophil count in 90% of patients.

About 1000 people in the United States have RPE65 gene mutations and inherited retinal diseases.

The investigational anti-fibrotic immunomodulator is being investigated for respiratory, oncology, hepatology, and nephrology indications.

Investigators studied patients from 5 unrelated families to determine the genetic mutations causing the condition.

Research into a rare neurological disorder may help researchers working on more common diseases including autism and epilepsy.